MAP1LC3B and ovarian carcinoma: The paired comparison of IHC-positive staining percentages between LSD1 and LC3B in the same cohort of ovarian cancer patients revealed that LSD1 had a significantly higher percentage of positive staining compared to LC3B in 83 out of 88 cases (Figure 5C).